Meaghan Loy, MS, ALAT, SOT Associate Member and Category Director of In Vivo Services at Scientist.com reflects on a recent 3-part webinar series focusing…

Upsetting the status quo is never easy, especially when it comes to scientific research. Just ask AstraZeneca duo Natasha A. Karp, Associate Principal Scientist/ Biostatistician and Neil Reavey, Associate Director, Research Assurance, who explore ways of overcoming the issue of sex bias in a paper entitled, “Sex Bias in Preclinical Research and Exploration of How to Change the Status Quo.”

Most cellular processes are part of specific molecular pathways. A deep knowledge of each step of these pathways is important to tackle some of the key open questions within the life sciences and fight diseases.

In part I we examined the evolution of outsourcing in drug discovery. In part II we will examine with deeper focus the specific reasons why it is beneficial to outsource scientific experiments. Research organizations and even individual researchers outsource for a variety of reasons, but here are just a few.

 A recent white paper was released that traces the trajectory over the last ten years of 120 independent for-profit startups in the field of research workflows and scholarly communication. The author, Yvonne Campfens, presented the report at the Academic Publishing in Europe (APE) Conference held January 15-16, 2019 in Berlin.